This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Institut Pasteur De Lille, National Institute of Health and Medical Research. Active years: 2026.
Company Filing History:
1 out of 5,383 
1 out of 65 
1 out of 1,853 
Years Active: 2026
Title: Arnaud Machelart: Innovator in Tuberculosis Treatment
Introduction
Arnaud Machelart is a notable inventor based in Lille, France. He has made significant contributions to the field of medicine, particularly in the treatment of tuberculosis. His innovative approach addresses the challenges faced by patients undergoing lengthy and complex treatment regimens.
Latest Patents
Machelart holds a patent for the "Use of materials made of cross-linked β-cyclodextrins for the treatment of tuberculosis." This invention is particularly relevant as multi-drug resistant tuberculosis (TB) poses a major public health challenge, affecting approximately half a million cases annually. Current treatment protocols require patients to adhere to a regimen involving over 10,000 tablets over a two-year period. Machelart's research indicates that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) serve as effective vehicles for the pulmonary delivery of potent combinations of anti-TB drugs. Furthermore, these nanoparticles exhibit intrinsic antibacterial properties, impairing the establishment of Mycobacterium tuberculosis (Mtb) after pulmonary administration in mice.
Career Highlights
Throughout his career, Machelart has worked with esteemed institutions such as the National Institute of Health and Medical Research and Université De Lille. His research has focused on developing better-formulated medications that enhance patient adherence and treatment efficacy.
Collaborations
Machelart has collaborated with notable colleagues, including Alain Boulard and Ruxandra Gref. Their combined expertise has contributed to the advancement of innovative solutions in the fight against tuberculosis.
Conclusion
Arnaud Machelart's work exemplifies the critical role of innovation in addressing public health challenges. His patent on cross-linked β-cyclodextrins represents a promising advancement in tuberculosis treatment, potentially improving patient outcomes and adherence to therapy.